Celldex Therapeutics (Celldex) has reported positive results from a Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers. Reportedly,
ChemGenex Pharmaceuticals (ChemGenex) and Hospira have entered into an exclusive agreement to license, develop and commercialise the former’s omacetaxine mepesuccinate, a targeted cytotoxic pharmaceutical product, in Europe, the
Bioo Scientific has launched T3 Conjugation Kit which allows scientists to deliver siRNA into targeted cell types. The company’s patent pending Kit can also be used for targeted
Elan Drug Technologies, a business unit of Elan, receives approval from the Japanese Ministry of Health, Labour and Welfare for Emend (aprepitant) for the treatment of cancer chemotherapy-induced
Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, have announced that the clinical development program in metastatic triple-negative breast cancer (mTNBC) for the investigational PARP1 inhibitor, BSI-201, progresses as
Icon has expanded its European central laboratory, located in South County Business Park, Dublin. The newly-designed 41,000sft (3,800m²) facility, which is three times the size of the previous
Instem has established an office in Shanghai to provide local customer support, service delivery, client management, development and sales support to the Chinese pharmaceutical and wider life sciences
SinoFresh HealthCare Products (SinoFresh) has reported a positive initial pilot animal study of its Nasal Spray product for use in preventing and decreasing the severity of H1N1 (swine
Yissum Research Development, the technology transfer arm of the Hebrew University of Jerusalem, has presented EtoClean, a new antiviral hand sanitizer which has been found to be effective
Revolutions Medical has initiated the mass manufacturing process for the FDA approved RevVac, an easy to use, single-handed vacuum safety syringe. By hitting its primary milestone, RevMed satisfies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.